הכנסה תפעולית לפני ניכוי פחת: Cryo-Cell International (CCEL)

Cryo-Cell International (CCEL) is implementing sustainable ESG standards in cryogenic storage, enhancing biodata security. Aggregated EBITDA demonstrates a daily cash inflow, with the current level sitting around 1.53. Profit growth is driven by the number of new contracts and the development of regenerative medicine. Stable annual client fees guarantee a predictable cash flow and eliminate liquidity gaps.

This indicator measures the actual cash flow generated by operating activities during a period of expensive liquidity and tight monetary policy. By analyzing the EBITDA of Cryo-Cell International (CCEL) on the GURU.Markets platform, an investor assesses the business's resilience to high interest rates, which for Cryo-Cell International (CCEL) is confirmed by the stability of its core biochemist team and low attrition among specialized professionals.